ArticleTranslational oncology2026
Comprehensive investigation of hypoxia-associated genes and their predictive significance in osteosarcoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn accumulation of evidence underscores the critical importance of both hypoxia and the immune microenvironment in driving the progression of osteosarcoma. Despite advancements in therapeutic strategies, osteosarcoma continues to pose a formidable challenge due to its aggressive nature and high metastatic potential. Nonetheless, the identification of reliable gene signatures that combine information on hypoxia and immune status to predict osteosarcoma prognosis remains an unmet need.
methodsTo gain a deeper understanding of the impact of hypoxia on the invasion of osteosarcoma, we devised a data-driven modeling framework, termed Cellular Hypoxia Prediction Framework (CHPF), which integrates single-cell transcriptome profiling with hypoxia gene signatures to predict cellular hypoxia status. We applied dimensionality reduction, clustering, and various analytical tools such as WGCNA, GO enrichment, and CellChat for cell-cell communication analysis.
resultsWe conducted a comprehensive analysis of the hypoxia status landscape within osteosarcoma cells and observed a distinct pattern, where hypoxic cells were predominantly confined to the tumor core region. Our analysis revealed distinct hypoxic subpopulations within osteosarcoma, with significant overexpression of genes like FGFBP2 and S100A1 in hypoxic cells. Remarkably, our investigation delved into the functional heterogeneity of tumor cells and uncovered a hypoxic subpopulation that exhibited a remarkably high invasive potential. We identified key genes (RPS28, ZC3HAV1, RPS8, S100A13, SERPINH1, EFNA5, RPL37A, USP11) that are associated with patient prognosis and developed a predictive model, which categorized patients based on their risk profiles. Hypoxia upregulates SERPINH1 expression in osteosarcoma cells in a HIF‑1α‑dependent manner, promotes proliferation and invasion, and SERPINH1 knockdown effectively reverses these hypoxia‑induced malignant phenotypes.
conclusionGenes associated with hypoxia play a pivotal role in the biology of osteosarcoma, significantly impacting tumor behavior and patient survival outcomes. Our research findings offer valuable insights into the underlying mechanisms of osteosarcoma and could potentially pave the way for the development of innovative therapeutic approaches that specifically target the hypoxic tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.